And it’s not just the number of new approvals that’s a problem , it’s also the nature  of those approvals.   In the words of Joseph V. Gulfo, executive director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University:   Cardiovascular disease remains the number cause of death in the United States, yet, not one drug to treat primary cardiovascular disease was approved in 2016.   